Kingmed Diagnostics(SH:603882) Xin Lang Cai Jing·2026-01-19 01:43Group 1 - The core viewpoint of the news is that Kingmed Diagnostics experienced a significant drop in stock price, with a decline of 9.37% on January 16, resulting in a trading volume of 1.084 billion yuan [1] - On January 16, Kingmed Diagnostics had a financing buy-in amount of 100 million yuan, with a net financing buy of -14.32 million yuan, indicating a higher level of financing activity compared to the past year [1] - The total financing and securities balance for Kingmed Diagnostics as of January 16 is 530 million yuan, which accounts for 3.53% of its market capitalization, indicating a high financing balance relative to historical levels [1] Group 2 - Kingmed Diagnostics provides a wide range of medical testing services, including nearly 80 types of testing technologies and approximately 3,200 testing projects to over 23,000 medical institutions across China [2] - The company's main business revenue composition includes 91.20% from medical diagnostic services, 6.45% from sales of diagnostics, and smaller contributions from other services [2] - For the period from January to September 2025, Kingmed Diagnostics reported a revenue of 4.538 billion yuan, reflecting a year-on-year decrease of 19.23%, and a net profit attributable to shareholders of -79.6095 million yuan, a decline of 184.84% [2] Group 3 - Since its A-share listing, Kingmed Diagnostics has distributed a total of 2.545 billion yuan in dividends, with 1.647 billion yuan distributed over the past three years [3] - As of September 30, 2025, the top ten circulating shareholders of Kingmed Diagnostics include Hong Kong Central Clearing Limited as the second-largest shareholder, holding 35.5057 million shares, a decrease of 2.8676 million shares from the previous period [3] - The investment fund "Zhaoshang Advantage Enterprise Mixed A" has exited the list of the top ten circulating shareholders [3]